We appreciate the article by Eric Suba, highlighting some inadequacies in trials comparing various methods of screening for cervical cancer. Our response pertains to his reference to the Office for Human Research Protections (OHRP) raising concerns about issues relating to informed consent. We wish to present our perspective on the process of "informing" and "consenting" vulnerable patients in low-and middle-income countries (LMICs).